(2006-01-09) Biocad
New Russian medical preparation Leucostim significantly improves effectiveness and availability in modern treatment of oncological deseases.
Russian biotech company Biocad has successfully completed a multicenter comparative clinical trial of the first domestic granulocyte colony stimulating factor Leucostim. This trial was performed in three leading Moscow cancer centers. Leucostim was used for the treatment of 80 cancer patients with neutropenia after cytotoxic chemotherapy. 100% efficacy of Leucostim was demonstrated; its effect was profound and stable.
Results of the trial have proved that Leucostim has an excellent safety profile and a remarkable efficacy. Therefore Leucostim can be recommended for clinical use for treatment and prophylaxis of chemotherapy-related neutropenia.
All research that resulted in development of Leucostim was performed by Russian scientists. ZAO Biocad manufactures Leucostim in its ultramodern facility in Moscow region according to GMP regulations.
The launch of Leucostim is expected in mid-2006. Availability of this generic drug will make the effective therapy of cancer more affordable, which is of special importance for pediatric oncology and hematology. Therefore, by introducing this product into the Russian market Biocad contributes to the initiatives of the President of Russian Federation who has recently stipulated in the “Health” National Program that availability of hi-tech medical help has to be a priority.
Introduction of the first domestic granulocyte colony stimulating factor Leucostim into the medical practice now depends on whether governmental regulatory bodies will keep to the usual drug approval schedule.
Biocad
143422 P.O.Box 26
Moscow area
Krasnogoeskiy region,
Petrovo-Dalnee,
ellennnpr@gmail.com